Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.

ABSTRACT:

Introduction

The present study aimed to evaluate the effects of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on clinical and safety outcomes including glycemic control and cardiometabolic indicators using network meta-analysis.

Methods

MEDLINE, Embase, and Cochrane Library Central Register of Controlled Trials were searched from inception through June 30, 2019. Randomized clinical trials comparing one or more of six eligible GLP-1RAs with placebo or another eligible GLP-1RA were identified. We further screened studies that had 24-30 week follow-up periods and target endpoints. The primary outcome was change in hemoglobin A_1c (HbA_1c). Secondary outcomes included additional glycemic control indicators, cardiometabolic measures, and adverse events.

SUBMITTER: Jiang Y 

PROVIDER: S-EPMC7932945 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature